Vergelijking

Amycretin vs. CagriSema

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

CagriSema

CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Amycretin	CagriSema
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Amycretin

Volledige vermelding →

CagriSema

Volledige vermelding →

Frequently asked questions

What is the difference between Amycretin and CagriSema?: Amycretin is classified as "Metabool", while CagriSema is classified as "Metabool". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or CagriSema?: The highest available evidence level is "Humane RCT" for Amycretin and "Humane RCT" for CagriSema. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and CagriSema in Germany and the United States?: Duitsland: Amycretin — Niet goedgekeurd, CagriSema — Niet goedgekeurd. Verenigde Staten: Amycretin — Niet goedgekeurd, CagriSema — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

CagriSema

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Amycretin and CagriSema?

Amycretin is classified as "Metabool", while CagriSema is classified as "Metabool". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or CagriSema?

The highest available evidence level is "Humane RCT" for Amycretin and "Humane RCT" for CagriSema. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and CagriSema in Germany and the United States?

Duitsland: Amycretin — Niet goedgekeurd, CagriSema — Niet goedgekeurd. Verenigde Staten: Amycretin — Niet goedgekeurd, CagriSema — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.